Janssen Vaccines & Prevention

Janssen Vaccines & Prevention, a subsidiary of Johnson & Johnson, is a global biotechnology leader dedicated to developing vaccines for high-threat infectious diseases. Headquartered in Leiden, Netherlands, the company leverages its proprietary AdVac viral vector technology and PER.C6 manufacturing cell line to accelerate the production of vaccines. Their portfolio includes the first European-approved Ebola vaccine regimen and a widely deployed single-dose COVID-19 vaccine. The company maintains a robust pipeline targeting significant global health challenges such as RSV, HIV, and antimicrobial-resistant bacterial infections. In 2023, as part of a broader corporate strategy, the entity began transitioning under the unified Johnson & Johnson Innovative Medicine brand.